Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Summit Corporation PLC Announces New Data From Preclinical Efficacy Study Of Oga Inhibitors

Monday, 11 Mar 2013 03:01am EDT 

Summit Corporation PLC announced new data from OGA (O-linked N-acetylglucosaminidase) inhibitor programme for the treatment of tauopathies, a group of neurodegenerative diseases that includes Alzheimer's disease. The OGA inhibitors were evaluated in an in vivo disease model, with results showing trends to a positive impact on motor impairment symptoms and improved survival rates following daily oral dosing. The study evaluated the OGA inhibitors, previously identified using Seglin technology, in a transgenic tauopathy disease model to determine the effect that prolonged dosing had on motor impairments related to the disease and survival rates. The tauopathies are also characterised by reduced levels of O-GlcNAcylated tau protein and raised levels of hyper-phosphorylated tau protein. In summary, the results of daily oral dosing with the Seglin inhibitors for 10 weeks were clear trend for reduced clasping, a clinical sign indicative of motor impairment, and improved survival rates compared to the untreated cohort; statistically increase in O-GlcNAcylated protein levels in the brain with the increased global levels maintained on repeat dosing to demonstrate that the OGA inhibitor accessed the brain compartment at therapeutically relevant concentrations; no observed change in tau protein phosphorylation levels although this is consistent with precedent from the scientific literature; no associated toxicity or adverse effects from prolonged dosing observed. 

Company Quote

4.0 +2.92%
24 Dec 2014